You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
偉思醫療(688580.SH)上半年不考慮股份支付費用影響純利升44.33% 研發投入大增84.21% 經營現金流升329.87%
格隆匯 07-27 17:33

格隆匯7月27日丨偉思醫療(688580.SH)發佈公吿,2021年半年度,公司實現營業總收入19,143.05萬元,同比增長21.91%;歸屬於上市公司股東的淨利潤6,918.16萬元,同比增長28.99%,歸屬於上市公司股東的扣除非經常性損益的淨利潤5,764.83萬元,同比增長17.74%。

公司實施《2021年限制性股票激勵計劃》產生的股份支付費用税後影響金額為822.91萬元,在不考慮股份支付費用影響下,公司2021年上半年實現歸屬於上市公司股東的淨利潤為7,741.07萬元,同比增長44.33%。

經營活動產生的現金流量淨額同比增長329.87%,主要系經營規模擴大帶來的資金量增長。上半年公司研發投入合計2812萬元,同比大增84.21%。研發投入總額佔營業收入比例達14.69%,同比上升4.97個百分點。

截至2021年6月30日,公司及其子公司擁有授權專利86項(其中發明專利15項)、軟件着作權53項、國內第二類醫療器械註冊證13項、進口醫療器械產品註冊證2項、第一類醫療器械產品備案憑證3項。其中,報吿期內,新增授權專利13項;新增軟件着作權2項;新增國內第二類醫療器械註冊證2項。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account